Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion

R Dummer, P A Ascierto, N Basset-Seguin, B Dréno, C Garbe, R Gutzmer, A Hauschild, R Krattinger, J T Lear, J Malvehy, D Schadendorf, J J Grob, R Dummer, P A Ascierto, N Basset-Seguin, B Dréno, C Garbe, R Gutzmer, A Hauschild, R Krattinger, J T Lear, J Malvehy, D Schadendorf, J J Grob

Abstract

Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only targeted treatment available for patients with locally advanced BCC (laBCC) in cases where surgery and radiotherapy are inappropriate. Sonidegib has recently been approved and now presents an alternative treatment option. The clinical differences between the two HhIs in patients with laBCC are unclear, as no head-to-head randomized controlled trials are or will be initiated. Moreover, there were important differences in the designs of their pivotal studies, BOLT (sonidegib) and ERIVANCE (vismodegib), and these differences complicate evidence-based analysis of their relative efficacy and safety profiles. In this paper, a group of clinical experts in the management of laBCC summarizes the clinical and pharmacological profiles of sonidegib and vismodegib based on published data and their own clinical experience. One key difference between the two pivotal studies was the criteria used to assess BCC severity. ERIVANCE (a single-arm phase II trial) used the conventional Response Evaluation Criteria in Solid Tumors (RECIST), while the more recent double-blind randomized BOLT trial used the stringent modified RECIST. A preplanned analysis adjusted the outcomes from BOLT with RECIST-like criteria, and this enabled the experts to discuss relative efficacy outcomes for the two treatments. Centrally reviewed objective response rate (ORR) for vismodegib was 47.6% (95% CI: 35.5-60.6) at 21-month follow-up using RECIST. After adjusting with RECIST-like criteria, the ORR for sonidegib according to central review at 18-month follow-up was 60.6% (95% CI: 47.8-72.4). Both treatments were associated with similar patterns of adverse events. Sonidegib and vismodegib share the same efficacy and tolerability profiles, but their pharmacokinetic profiles show several differences, such as volume of distribution and half-life. Further studies are needed to understand how these differences may impact clinical practice.

© 2020 European Academy of Dermatology and Venereology.

References

    1. Trakatelli M, Morton C, Nagore E et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014; 24: 312-329.
    1. Telfer NR, Colver GB, Morton CA. British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
    1. Migden MR, Chang AL, Dorox L et al. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev 2018; 64: 1-10.
    1. Dreier J, Cheng PF, Bogdan Alleman I et al. Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol 2014; 171: 1066-1072.
    1. Lear JT, Corner C, Dziewulski P et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer 2014; 111: 1476-1481.
    1. Mohan SV, Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep 2014; 3: 40-45.
    1. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol 2016; 8: 375-382.
    1. Nägeli MC, Dummer R. Vismodegib (Erivedge®). Schweiz Med Forum 2014; 14: 284-286.
    1. Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.
    1. European Medicines Agency. EMA/297688/2013 - Erivedge: EPAR - Public assessment report, 2013. URL (last accessed: January 25, 2019).
    1. Migden MR, Guminski A, Gutzmer R et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716-728.
    1. European Medicines Agency. EMA/472165/2015 - Odomzo: EPAR - Public assessment report, 2015. URL (last accessed: January 25, 2019).
    1. Odom D, Mladsi D, Purser M et al. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer 2017; 2017: 6121760.
    1. Pan S, Wu X, Jiang J et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 2010; 1: 130-134.
    1. Lear JT, Migden MR, Lewis KD et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32: 372-381.
    1. Graham RA, Lum BL, Cheeti S et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011; 17: 2512-2520.
    1. LoRusso PM, Jimeno A, Dy G et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 5774-5782.
    1. Lu T, Wang B, Gao Y et al. Semi-mechanism-based population pharmacokinetic modeling of the hedgehog pathway inhibitor vismodegib. CPT Pharmacometrics Syst Pharmacol 2015; 4: 680-689.
    1. Goel V, Hurh E, Stein A et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol 2016; 77: 745-755.
    1. Graham RA, Hop CE, Borin MT et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 2012; 74: 788-796.
    1. Zollinger M, Lozac'h F, Hurh E et al. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 2014; 74: 63-75.
    1. Fellner C. Vismodegib (erivedge) for advanced basal cell carcinoma. Pharm Ther 2012; 37: 670-682.
    1. Basset-Séguin N, Hauschild A, Kunstfeld R et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017; 86: 334-348.
    1. Dréno B, Kunstfeld R, Hauschild A et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol 2017; 18: 404-412.
    1. Dummer R, Guminski A, Gutzmer R et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016; 75: 113-125.
    1. Sekulic A, Migden MR, Lewis K et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 2015; 72: 1021-1026.
    1. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
    1. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
    1. Sekulic A, Migden MR, Basset-Seguin N et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017; 17: 332.
    1. Data on file. Sonidegib adverse events 21-month follow up. Sun Pharmaceuticals Industries, Ltd.
    1. Migden MR. Quality of life in advanced basal cell carcinoma and treatment with hedgehog inhibitors. J Clin Trials Res 2018; 1: 9-16.
    1. National Cancer Institute. A study evaluating the efficacy and safety of vismodegib (GDC-0449, hedgehog pathway inhibitor) in patients with advanced basal cell carcinoma, 2017. URL = 1 (last accessed: January 25, 2019).
    1. Hansson J, Bartley K, Grob JJ et al. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study. Eur J Dermatol 2018; 28: 775-783.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera